$0.7724−$0.007600 (−0.97%) on the dayAs of the close; data may be delayed.
INAB price, last 12 months
$2.59$0.7724
Daily closes over the last 260 trading sessions: −50.2%. Highest close $2.59 on , lowest $0.7724 on . Market data may be delayed.
Key stats
Previous close
$0.7800
Open
$0.7810
Day range
$0.7510 – $0.8315
52-week range
$0.7236 – $2.73
Volume
12.1K
Avg volume (20 days)
292.1K
Market cap
—
Performance
1W−8.3%
1M−23.7%
3M−36.3%
6M−55.0%
YTD−67.9%
1Y−53.6%
vs S&P 500, 1Y−58.9 pts
Technicals and fundamentals
About INAB
No company description is available yet.
Listed on
NASDAQ
Market cap
—
Recent news about INAB
Chart INAB with indicators, scan for setups and get alerts
This page is open to everyone. A free ScanPro account adds the interactive parts, along with watchlists, paper trading with simulated money and the Academy's quizzes.
A full INAB chart with indicator overlays, pattern markers and daily, weekly or intraday bars.
Scans of a whole index or list with 72 named conditions, 26 chart setups or a formula of your own.
Alerts and notifications when one fires on a stock you watch, on delayed market data.
Daily range (ATR)11.8%average true range, % of price
52w low $0.723652w high $2.73
Where price sits today against its own history. A description, not a forecast.
Valuation
P/E (trailing)—
P/E (forward)−0.8
PEG—
Price / sales—
Price / book0.54
EV / EBITDA—
Company figures as of Nov 19, 2026.
Analysts
ConsensusStrong buy1.3 on 1 (strong buy) to 5 (strong sell)
Analysts3
Average target$7.00+830.6% from today
Price targets are opinions and tend to lean optimistic. Only 3 analysts cover it, so one view moves the average.
Earnings
Next results, expectedaround Mar 11, 2027 (in 111 days)A year after its Mar 12, 2026 results release; the last came Nov 5, 2026. An estimate from its SEC filings, not a date the company announced.
Seasonality
-9.2
J
-6.4
F
-16.1
M
-5.6
A
+26.4
M
-30.7
J
-7.3
J
-7.3
A
-10.5
S
-6.2
O
-7.7
N
+15.3
D
Average return in each calendar month, Oct 31, 2021 to Oct 31, 2026. 6 years is 6 observations a month: too few to call a pattern, so read it as history, not a calendar to trade.
Year by year
Year
J
F
M
A
M
J
J
A
S
O
N
D
Year
2026
−16
−14
−13
−1
+27
−25
−27
+6
+21
−32
−61%
2025
−1
+5
−38
+2
−12
−53
+2
+4
−2
−10
+2
+18
−70%
2024
−6
−15
+6
−14
+17
−29
−1
−37
−49
+4
+9
−16
−81%
2023
−1
−33
−15
+12
+108
−49
−23
−11
−1
−6
−15
+66
−40%
2022
−23
+25
−21
−28
−8
+2
+12
+2
−22
−3
−11
+33
−47%
2021
+11
−23
−25
−36%
Each year's monthly returns in %, the observations behind the averages. The last column compounds the year's months; a year the history only partly covers is faded.
Financials
As reported in the company's SEC filings. Latest: Q3 FY2026, ended Sep 30, 2026.
Free shows the latest quarter, the latest year and the last 12 months. Plus shows every period and the growth figures.See Plus
Figures are as each 10-Q and 10-K reported them, in the company's own fiscal calendar, not restated later. A company that changes how it reports a line can make one period look out of step with the rest. Growth compares the same period a year earlier and is left blank when the year before was a loss. Banks and insurers report no gross profit, so rows they don't file are left out. Every filing on SEC EDGAR
The announcement is a routine corporate action regarding employee stock option grants. While it indicates the company is hiring and investing in talent, this is standard practice for biopharmaceutical companies and does not provide material information about business performance, clinical progress, or financial health.
The company is actively advancing its clinical pipeline with multiple programs in development (INB-600, INB-100, INB-200/400) and securing investor engagement opportunities at major conferences. The appointment of a Senior Vice President of R&D and participation in investor conferences indicate positive momentum and confidence in the company's direction.
Tone is the news provider's automated reading of each article for this stock. It describes the article, not what the price will do.
Figures describe the past, not what the price will do next. Educational tools, not investment advice.